REG - GlaxoSK Capital PLC - Publication of a Prospectus

Great-West LifecoAnnouncement

08/12/2021 14:35

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211208:nRSH0108Va&default-theme=true

RNS Number : 0108V  GlaxoSmithKline Capital PLC  08 December 2021

Publication of Base Prospectus

 

The following base prospectus dated 8 December 2021 has been approved by the
Financial Conduct Authority and is available for viewing:

GlaxoSmithKline plc, GlaxoSmithKline Capital plc, GSK Capital B.V. and GSK
Capital K.K. £20,000,000,000 Euro Medium Term Note Programme

Copies of the base prospectus and the documents incorporated by reference
within it have been submitted to the UK Listing Authority's NSM submission
portal via the Electronic Submission System (ESS). The base prospectus will
shortly be available for inspection at and can be downloaded from:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

For further information, please contact:

GlaxoSmithKline plc

980 Great West Road

Brentford

Middlesex

TW8 9GS

United Kingdom

Enquiries:

 UK Media enquiries:                   David Mawdsley   +44 (0) 20 8047 5502   (London)

                                       Simon Steel      +44 (0) 20 8047 5502   (London)

                                       Tim Foley        +44 (0) 20 8047 5502   (London)
 European Analyst/Investor enquiries:  James Dodwell    +44 (0) 20 8047 2406   (London)

                                       Danielle Smith   +44 (0) 20 8047 0932   (London)

 

BASIS ON WHICH YOU MAY ACCESS THE BASE PROSPECTUS

Please note that the information contained in the base prospectus may be
addressed to and/or targeted at persons who are residents of particular
countries (specified in the base prospectus) only and is not intended for use
and should not be relied upon by any person outside these countries and/or to
whom the offer contained in the base prospectus is not addressed. Prior to
relying on the information contained in the base prospectus you must ascertain
from the base prospectus whether or not you are part of the intended
addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above
requirements.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PDIBXBDDBXGDGBI